# EDGAR Filing Document

**Accession Number:** 0001612940
**File Stem:** 0001104659-26-005130
**Filing Date:** 2026-1
**Character Count:** 19815
**Document Hash:** f05d4759b034e1b6b9825ffa2df48f77
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-005130.hdr.sgml**: 20260120

**ACCESSION NUMBER**: 0001104659-26-005130

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260120

**DATE AS OF CHANGE**: 20260120

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProQR Therapeutics N.V.
- **CENTRAL INDEX KEY:** 0001612940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88671
- **FILM NUMBER:** 26543931

**BUSINESS ADDRESS:**
- **STREET 1:** ZERNIKEDREEF 9
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CK
- **BUSINESS PHONE:** 31 88 166 7000

**MAIL ADDRESS:**
- **STREET 1:** ZERNIKEDREEF 9
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CK

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProQR Therapeutics B.V.
- **DATE OF NAME CHANGE:** 20140708
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Privium Fund Management B.V.
- **CENTRAL INDEX KEY:** 0001795097

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** GUSTAV MAHLERPLEIN 3
- **CITY:** AMSTERDAM
- **STATE:** P7
- **ZIP:** 1082 MS
- **BUSINESS PHONE:** 31 20 462 6644

**MAIL ADDRESS:**
- **STREET 1:** GUSTAV MAHLERPLEIN 3
- **CITY:** AMSTERDAM
- **STATE:** P7
- **ZIP:** 1082 MS

## Exhibit 99.1

**Exhibit 99.1**

**Joint Filing Agreement**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

---

| | |
|:---|:---|
| Date: January 20, 2026 | Date: January 20, 2026 |
| **STICHTING AESCAP LIFE SCIENCES** | **STICHTING AESCAP LIFE SCIENCES** |
| **BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER** | **BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER** |
| By: | /s/ P.J.H. Krol |
| Name: | P.J.H. Krol |
| Title: | Portfolio Manager |
| **STICHTING AESCAP GENETICS** | **STICHTING AESCAP GENETICS** |
| **BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER** | **BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER** |
| By: | /s/ P.J.H. Krol |
| Name: | P.J.H. Krol |
| Title: | Portfolio Manager |
| **PRIVIUM FUND MANAGEMENT B.V.** | **PRIVIUM FUND MANAGEMENT B.V.** |
| By: | /s/ P.J.H. Krol |
| Name: | P.J.H. Krol |
| Title: | Portfolio Manager |
| **INSPIRATIONAL VISIONS B.V.** | **INSPIRATIONAL VISIONS B.V.** |
| By: | /s/ P.J.H. Krol |
| Name: | P.J.H. Krol |
| Title: | Managing Director |
| **PATRICK JOHAN HENDRIK KROL** | **PATRICK JOHAN HENDRIK KROL** |
|  | /s/ P.J.H. Krol |
| Dated: January 20, 2026 | Dated: January 20, 2026 |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** ProQR Therapeutics N.V.

**Title of Class of Securities:** Ordinary Shares, nominal value EUR0.04 per share

**CUSIP Number:** N71542109

**Date of Event Which Requires Filing of this Statement:** 12/11/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>STICHTING AESCAP LIFE SCIENCES | Names of Reporting Persons<br>STICHTING AESCAP LIFE SCIENCES |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4156878.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4156878.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4156878.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4156878.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>3.9% | Percent of Class Represented by Amount in Row (9)<br>3.9% |
| 12. | Type of Reporting Person (See Instructions)<br>FI | Type of Reporting Person (See Instructions)<br>FI |

**Comment for Type of Reporting Person:** (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.

---

| 1. | Names of Reporting Persons<br>PRIVIUM FUND MANAGEMENT B.V. | Names of Reporting Persons<br>PRIVIUM FUND MANAGEMENT B.V. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>5467149.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>5467149.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5467149.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5467149.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.2% | Percent of Class Represented by Amount in Row (9)<br>5.2% |
| 12. | Type of Reporting Person (See Instructions)<br>FI | Type of Reporting Person (See Instructions)<br>FI |

**Comment for Type of Reporting Person:** (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.

---

| 1. | Names of Reporting Persons<br>STICHTING AESCAP GENETICS | Names of Reporting Persons<br>STICHTING AESCAP GENETICS |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>1310271.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>1310271.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1310271.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1310271.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.2% | Percent of Class Represented by Amount in Row (9)<br>1.2% |
| 12. | Type of Reporting Person (See Instructions)<br>FI | Type of Reporting Person (See Instructions)<br>FI |

**Comment for Type of Reporting Person:** (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.

---

| 1. | Names of Reporting Persons<br>INSPIRATIONAL VISIONS B.V. | Names of Reporting Persons<br>INSPIRATIONAL VISIONS B.V. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>35411.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>35411.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>35411.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>35411.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.1% | Percent of Class Represented by Amount in Row (9)<br>0.1% |
| 12. | Type of Reporting Person (See Instructions)<br>FI | Type of Reporting Person (See Instructions)<br>FI |

**Comment for Type of Reporting Person:** (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.

---

| 1. | Names of Reporting Persons<br>PATRICK JOHAN HENDRIK KROL | Names of Reporting Persons<br>PATRICK JOHAN HENDRIK KROL |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>P7 | Citizenship or Place of Organization<br>P7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>5528862.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>5528862.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5528862.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5528862.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.2% | Percent of Class Represented by Amount in Row (9)<br>5.2% |
| 12. | Type of Reporting Person (See Instructions)<br>FI | Type of Reporting Person (See Instructions)<br>FI |

**Comment for Type of Reporting Person:** (1) Based upon 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in the Issuer's Report of Foreign Private Issuer on Form 6-K filed on November 6, 2025.

---

**Item 1(a). Name of Issuer:**
ProQR Therapeutics N.V.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
Zernikedreef 9 Leiden, The Netherlands, CK 2333

**Item 2(a). Name of Person Filing:**
(i) Stichting Aescap Life Sciences ("Aescap Life Sciences")

(ii) Privium Fund Management B.V. ("Privium"), as the fund manager of Aescap Life Sciences

(iii) Stichting Aescap Genetics ("Aescap Genetics")

(iv) Inspirational Visions BV ("Inspirational Visions")

(v) Patrick Johan Hendrik Krol ("Krol"), the portfolio manager for Privium regarding Aescap Life Sciences and Aescap Genetics and the managing director of Inspirational Visions

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

**Item 2(b). Address of Principal Business Office:**
The principal business address of each of Aescap Life Sciences, Privium, Aescap Genetics and Krol is:

Gustav Mahlerplein 3
1082 MS Amsterdam
The Netherlands

The principal business address of Inspirational Visions is:

A.J. Ernststraat 595-C
1082 LN Amsterdam
The Netherlands

**Item 2(c). Citizenship:**
The citizenship of each of the Reporting Persons is the Netherlands.

**Item 2(d). Title of Class of Securities:**
Ordinary Shares, nominal value EUR0.04 per share

**Item 2(e). CUSIP Number:**
N71542109

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed to beneficially own the Shares held by Aescap Life Sciences and Aescap Genetics. In addition, as the managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by Inspirational Visions.
As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares. As of the date of this report, Aescap Genetics directly held 1,310,271 Shares. As of the date of this report, Inspirational Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares.

**(b) Percent of class:**

Aescap Life Sciences may be deemed the beneficial owner of approximately 3.9% of the Shares outstanding.
Privium may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding.
Aescap Genetics may be deemed the beneficial owner of approximately 1.2% of the Shares outstanding.
Inspirational Visions may be deemed the beneficial owner of approximately 0.1% of the Shares outstanding.
Krol may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Aescap Life Sciences: 4,156,878
Privium: 5,467,149
Aescap Genetics: 1,310,271
Inspirational Visions: 35,411
Krol: 5,528,862

**(ii) Shared power to vote or to direct the vote:**

Aescap Life Sciences: 0
Privium: 0
Aescap Genetics: 0
Inspirational Visions: 0
Krol: 0

**(iii) Sole power to dispose or to direct the disposition of:**

Aescap Life Sciences: 4,156,878
Privium: 5,467,149
Aescap Genetics: 1,310,271
Inspirational Visions: 35,411
Krol: 5,528,862

**(iv) Shared power to dispose or to direct the disposition of:**

Aescap Life Sciences: 0
Privium: 0
Aescap Genetics: 0
Inspirational Visions: 0
Krol: 0

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**STICHTING AESCAP LIFE SCIENCES**

**Date:** 01/20/2026

**By:** /s/ P.J.H. Krol

**Name & Title:** P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager

**PRIVIUM FUND MANAGEMENT B.V.**

**Date:** 01/20/2026

**By:** /s/ P.J.H. Krol

**Name & Title:** P.J.H. Krol, Portfolio Manager

**STICHTING AESCAP GENETICS**

**Date:** 01/20/2026

**By:** /s/ P.J.H. Krol

**Name & Title:** P.J.H. Krol, Portfolio Manager of Privium Fund Management B.V., its Fund Manager

**INSPIRATIONAL VISIONS B.V.**

**Date:** 01/20/2026

**By:** /s/ P.J.H. Krol

**Name & Title:** P.J.H. Krol, Managing Director

**PATRICK JOHAN HENDRIK KROL**

**Date:** 01/20/2026

**By:** /s/ P.J.H. Krol

**Name & Title:** P.J.H. Krol